Clinical Trials Browser

Phase 2 × Recruiting × Mycosis Fungoides × Clear all

Lymphoma, Non-Hodgkin, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT05680558 2026-04-27

Photopheresis in Early-stage Mycosis Fungoides

Phase 2 Recruiting

74 enrolled

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT03398161 2026-04-15

Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides

Phase 2 Recruiting

50 enrolled

Lymphoid

Mycosis Fungoides

NCT03587844 2026-04-03

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Phase 2 Recruiting

58 enrolled

Lymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis

NCT05357794 2026-01-12

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Phase 2 Recruiting

30 enrolled

Lymphoid

Mycosis Fungoides

NCT06716658 2025-11-18

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Phase 2 Recruiting

48 enrolled

DermatologicLymphoidOther hematologic neoplasm

Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Leukemia, Large Granular Lymphocytic

NCT04930653 2025-10-14

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Phase 2 Recruiting

34 enrolled

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT04256018 2025-07-02

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

Phase 2 Recruiting

30 enrolled

Lymphoid

Mycosis Fungoides, Sezary Syndrome

Clinical Trials

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Photopheresis in Early-stage Mycosis Fungoides

Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome